Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates

Bioanalysis

Volumn 5, Issue 9, 2013, Pages 1041-1055

  Hoofring, Sarah A ^a   Lopez, Rocio ^a   Hock, M Benjamin ^a   Kaliyaperumal, Arunan ^a   Patel, Sonal K ^b   Swanson, Steven J ^a   Chirmule, Narendra ^a   Starcevic, Marta ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; DRUG ANTIBODY; EPITOPE; PLACEBO;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FALSE NEGATIVE RESULT; IMMUNOASSAY; IMMUNOGENICITY; LOW DRUG DOSE; NONHUMAN; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; RAT; VALIDATION PROCESS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; HUMANS; IMMUNOCONJUGATES; IMMUNOGENETIC PHENOMENA; PHARMACEUTICAL PREPARATIONS;

EID: 84877303973     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.10     Document Type: Article

References (29)

1. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3(4), 349-360 (2002).
2. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24(11), 1720-1740; discussion 1719 (2002).
3. Ponce R, Abad L, Amaravadi L et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54(2), 164-182 (2009).
4. US Department of Health and Human Services, US FDA (CDER, CBER). Guidance for Industry-Assay Development for Immunogenicity Testing of Therapeutic Proteins (Draft). US Department of Health and Human Services, Washington, DC, USA (2009).
5. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
6. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25(5), 555-561 (2007).
7. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. European Medicines Agency, London, UK (2007).
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1). US Department of Health and Human Services, Washington, DC, USA (2011).
9. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004).
10. Swanson SJ, Bussiere J. Immunogenicity assessment in non-clinical studies. Curr. Opin. Microbiol. (15), 1-11 (2012).
11. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24(6), 274-280 (2006).
12. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14(4), 529-537 (2010).
13. Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted drug delivery using immunoconjugates: principles and applications. J. Immunother. 34(9), 611-628 (2011).
14. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17(20), 6389-6397 (2011).
15. Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol. 20(4), 493-499 (2008).
16. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 28(11), 482-490 (2007).
17. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: considering host-specific and product-specific factors impacting immunogenicity. Biopharm. Int. 17, 34-42 (2004).
18. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 1: considering consequences of the immune response to a protein. Biopharm. Int. 17, 22-26 (2004).
19. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 3: effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. Biopharm. Int. 18, 32-36 (2005).
20. Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol. Immunol. 46(3), 448-456 (2009).
21. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3(2), 161-172 (2011).
22. Stephan JP, Kozak KR, Wong WL. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3(6), 677-700 (2011).
23. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5(2), 201-226.
24. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278(1-2), 1-17 (2003).
25. Menendez AT. Strategic selection and development of immunogenicity binding methods. Bioanalysis 4(12), 1491-1508 (2012).
26. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 304(1-2), 189-195 (2005).
27. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J. Exp. Med. 181(2), 453-461 (1995).
28. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 8(3), E501-E507 (2006).
29. Shmagel KV, Chereshnev VA. Molecular bases of immune complex pathology. Biochemistry (Mosc.) 74(5), 469-479 (2009).